een 04 Mar 19 and 31 Jan 2020, 48 pts were enrolled and evaluated for safety and exposure. The median age was 66 yrs (range 48-84) and 73 % were male. The ECOG was 0 in 50 % and 1 in 50 % of pts, respectively. Pts received a median of 5 (7) and in total 311 (413) pembrolizumab (efti) administrations, respectively. Three pts (6.3 %) discontinued study treatment due to AEs. The most common ( > 10%) adverse events (AEs) being cough (31 %), asthenia (23 %), decreased appetite (19 %), fatigue (19 %), dyspnea (17 %), diarrhea (15 %) and constipation 13 %). From part A all pts (n = 17) were evaluated. Eight pts (47 %) had a partial response (iPR) and six (35 %) had stable disease according to iRECIST representing an ORR (DCR) of 47 % (82 %). irPRs were observed in all different PD-L1 groups ( < 1%; ≥ 1 % ≤49 %; ≥ 50 %). Ten (10; 59 %) pts are still on therapy (8+ months). In part C stage 1 15/18 pts are evaluable and six (40 %) had an iPR to date. Conclusions: Efti in combination with pembrolizumab is safe and shows encouraging antitumor activity in all comer PD-L1 1st line NSCLC and 2nd line HNSCC. Stage 2 has opened for both parts. Clinical trial information: NCT03625323
Just a reminder of the good INITIAL Stage trial results in otherwise unfavourable prognostic cohort
- Forums
- ASX - By Stock
- IMM
- Ann: Immutep expands Part B of TACTI-002 collaboration trial
Ann: Immutep expands Part B of TACTI-002 collaboration trial, page-4
-
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $493.8M |
Open | High | Low | Value | Volume |
33.5¢ | 34.0¢ | 33.0¢ | $1.233M | 3.670M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 484808 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.0¢ | 52319 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 484808 | 0.330 |
8 | 258954 | 0.325 |
13 | 518704 | 0.320 |
3 | 155001 | 0.315 |
4 | 23010 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.340 | 52319 | 5 |
0.345 | 49903 | 2 |
0.350 | 22702 | 4 |
0.355 | 125992 | 5 |
0.360 | 149360 | 5 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
IMM (ASX) Chart |